Cargando…

Prevalence of multidrug resistance among retreatment pulmonary tuberculosis cases in a tertiary care hospital, Hyderabad, India

BACKGROUND: India is one of the high tuberculosis (TB) burden countries in the world. India ranks second in harboring multi drug resistant (MDR)-TB cases. About 50,000 of MDR cases are recorded in retreatment pulmonary TB cases. This study was conducted in a tertiary care facility (Government Genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandi, Subhakar, Prasad, Surapaneni Venkateswara, Sagar Reddy, P. Navaneeth, Reddy, Vennaposa Chenna Kishore, Laxmi, Rajya, Kopuu, Dhanamurthy, Kondapaka, Kiran Kumar, Sreenivas Rao, M. S., Vishnu, P. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841681/
https://www.ncbi.nlm.nih.gov/pubmed/24339482
http://dx.doi.org/10.4103/0970-2113.120599
Descripción
Sumario:BACKGROUND: India is one of the high tuberculosis (TB) burden countries in the world. India ranks second in harboring multi drug resistant (MDR)-TB cases. About 50,000 of MDR cases are recorded in retreatment pulmonary TB cases. This study was conducted in a tertiary care facility (Government General and Chest Hospital) in Hyderabad, India. OBJECTIVES: Toassess: Proportion of the TB patients having MDR-TB at the initiation of retreatment regimen; the prevalence of isoniazid (INH) resistance in this geographical area. MATERIALS AND METHODS: An analytical, observational, prospective cohort study of patients attending the out-patient department from December 2010 to March 2011. RESULTS: Sputum samples from 100 patients were subjected to acid fast bacilli (AFB) culture and drug sensitivity testing. Of these, 28 (28%) were MDR-TB, 42 (42%) were non-MDR-TB and 39% being INH resistance. CONCLUSIONS: In conclusion, one third of the retreatment pulmonary TB cases attending a tertiary care institute for TB will be MDR-TB at the initiation of treatment and there is a need to include ethambutol in the continuation phase of new TB case treatment in view of high INH resistance.